Compare VKTX & CVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VKTX | CVSA |
|---|---|---|
| Founded | 2012 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.3B |
| IPO Year | 2014 | 1995 |
| Metric | VKTX | CVSA |
|---|---|---|
| Price | $33.58 | $130.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | $95.86 | ★ $150.00 |
| AVG Volume (30 Days) | ★ 1.9M | 307.7K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 13.92 |
| EPS | N/A | ★ 7.04 |
| Revenue | N/A | ★ $1,954,085,000.00 |
| Revenue This Year | N/A | $9.66 |
| Revenue Next Year | N/A | $6.58 |
| P/E Ratio | ★ N/A | $18.19 |
| Revenue Growth | N/A | ★ 9.27 |
| 52 Week Low | $22.96 | $96.08 |
| 52 Week High | $43.15 | $141.92 |
| Indicator | VKTX | CVSA |
|---|---|---|
| Relative Strength Index (RSI) | 47.04 | 53.82 |
| Support Level | $32.24 | $108.32 |
| Resistance Level | $35.24 | $133.69 |
| Average True Range (ATR) | 1.27 | 6.29 |
| MACD | 0.13 | 0.03 |
| Stochastic Oscillator | 33.76 | 47.49 |
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Covista Inc is an American healthcare educator, serving more than 97,000 students and supported by a community of alumni across five accredited institutions. Through personalized, tech-enabled education powered by faculty and colleagues, it expands access to healthcare careers and addresses the U.S. healthcare workforce shortage at scale.